BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 12822182)

  • 1. Synthesis of 2-(4-biphenylyl)quinoline-4-carboxylate and carboxamide analogs. New human neurokinin-3 (hNK-3) receptor antagonists.
    Saudi MN; Rostom SA; Fahmy HT; El Ashmawy IM
    Arch Pharm (Weinheim); 2003 Jun; 336(3):165-74. PubMed ID: 12822182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of a novel class of selective non-peptide antagonists for the human neurokinin-3 receptor. 2. Identification of (S)-N-(1-phenylpropyl)-3-hydroxy-2-phenylquinoline-4-carboxamide (SB 223412).
    Giardina GA; Raveglia LF; Grugni M; Sarau HM; Farina C; Medhurst AD; Graziani D; Schmidt DB; Rigolio R; Luttmann M; Cavagnera S; Foley JJ; Vecchietti V; Hay DW
    J Med Chem; 1999 Mar; 42(6):1053-65. PubMed ID: 10090788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and structure-activity relationships of carboxyflavones as structurally rigid CysLT1 (LTD4) receptor antagonists.
    Zwaagstra ME; Timmerman H; van de Stolpe AC; de Kanter FJ; Tamura M; Wada Y; Zhang MQ
    J Med Chem; 1998 Apr; 41(9):1428-38. PubMed ID: 9554876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stepwise modulation of neurokinin-3 and neurokinin-2 receptor affinity and selectivity in quinoline tachykinin receptor antagonists.
    Blaney FE; Raveglia LF; Artico M; Cavagnera S; Dartois C; Farina C; Grugni M; Gagliardi S; Luttmann MA; Martinelli M; Nadler GM; Parini C; Petrillo P; Sarau HM; Scheideler MA; Hay DW; Giardina GA
    J Med Chem; 2001 May; 44(11):1675-89. PubMed ID: 11356103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonpeptide tachykinin receptor antagonists. II. Pharmacological and pharmacokinetic profile of SB-222200, a central nervous system penetrant, potent and selective NK-3 receptor antagonist.
    Sarau HM; Griswold DE; Bush B; Potts W; Sandhu P; Lundberg D; Foley JJ; Schmidt DB; Webb EF; Martin LD; Legos JJ; Whitmore RG; Barone FC; Medhurst AD; Luttmann MA; Giardina GA; Hay DW
    J Pharmacol Exp Ther; 2000 Oct; 295(1):373-81. PubMed ID: 10992004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of a novel class of selective non-peptide antagonists for the human neurokinin-3 receptor. 1. Identification of the 4-quinolinecarboxamide framework.
    Giardina GA; Sarau HM; Farina C; Medhurst AD; Grugni M; Raveglia LF; Schmidt DB; Rigolio R; Luttmann M; Vecchietti V; Hay DW
    J Med Chem; 1997 Jun; 40(12):1794-807. PubMed ID: 9191956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonpeptide tachykinin receptor antagonists. III. SB 235375, a low central nervous system-penetrant, potent and selective neurokinin-3 receptor antagonist, inhibits citric acid-induced cough and airways hyper-reactivity in guinea pigs.
    Hay DW; Giardina GA; Griswold DE; Underwood DC; Kotzer CJ; Bush B; Potts W; Sandhu P; Lundberg D; Foley JJ; Schmidt DB; Martin LD; Kilian D; Legos JJ; Barone FC; Luttmann MA; Grugni M; Raveglia LF; Sarau HM
    J Pharmacol Exp Ther; 2002 Jan; 300(1):314-23. PubMed ID: 11752131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and structure-activity relationships of carboxylated chalcones: a novel series of CysLT1 (LTD4) receptor antagonists.
    Zwaagstra ME; Timmerman H; Tamura M; Tohma T; Wada Y; Onogi K; Zhang MQ
    J Med Chem; 1997 Mar; 40(7):1075-89. PubMed ID: 9089329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of the first non-peptide full agonists for the human bradykinin B(2) receptor incorporating 4-(2-picolyloxy)quinoline and 1-(2-picolyl)benzimidazole frameworks.
    Sawada Y; Kayakiri H; Abe Y; Mizutani T; Inamura N; Asano M; Hatori C; Aramori I; Oku T; Tanaka H
    J Med Chem; 2004 May; 47(11):2853-63. PubMed ID: 15139763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and 5-HT3 receptor affinity of new quinolinecarboxylic acid derivatives.
    Orjales A; Alonso-Cires L; López-Tudanca PL; Tapia I; Labeaga L; Mosquera R
    Drug Des Discov; 2000; 16(4):271-9. PubMed ID: 10807033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and biological evaluation of novel fluoro and iodo quinoline carboxamides as potential ligands of NK-3 receptors for in vivo imaging studies.
    Bennacef I; Tymciu S; Dhilly M; Lasne MC; Debruyne D; Perrio C; Barré L
    Bioorg Med Chem; 2004 Aug; 12(16):4533-41. PubMed ID: 15265501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Replacement of the quinoline system in 2-phenyl-4-quinolinecarboxamide NK-3 receptor antagonists.
    Giardina GA; Artico M; Cavagnera S; Cerri A; Consolandi E; Gagliardi S; Graziani D; Grugni M; Hay DW; Luttmann MA; Mena R; Raveglia LF; Rigolio R; Sarau HM; Schmidt DB; Zanoni G; Farina C
    Farmaco; 1999 Jun; 54(6):364-74. PubMed ID: 10443017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antagonistic effects of FR 173657 on human, pig, rabbit, and guinea pig kinin receptors: an in vitro study.
    Rizzi A; Gobeil F; Bogoni G; Calò G; Campobasso C; Inamura N; Regoli D
    Can J Physiol Pharmacol; 1997 Jun; 75(6):601-8. PubMed ID: 9276136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Senktide-induced gerbil foot tapping behaviour is blocked by selective tachykinin NK1 and NK3 receptor antagonists.
    Sundqvist M; Kristensson E; Adolfsson R; Leffler A; Ahlstedt I; Engberg S; Drmota T; Sigfridsson K; Jussila R; de Verdier J; Novén A; Johansson A; Påhlman I; von Mentzer B; Lindström E
    Eur J Pharmacol; 2007 Dec; 577(1-3):78-86. PubMed ID: 17920583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lithiation of functionalized fluoroquinolines: synthesis of dihalo-2-phenylquinoline-4-carboxamides and in vitro evaluation as NK-3 receptor ligands for medical imaging studies.
    Bennacef I; Tymciu S; Dhilly M; Mongin F; Quéguiner G; Lasne MC; Barré L; Perrio C
    J Org Chem; 2004 Apr; 69(7):2622-5. PubMed ID: 15049675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New quinoline NK3 receptor antagonists with CNS activity.
    Smith PW; Wyman PA; Lovell P; Goodacre C; Serafinowska HT; Vong A; Harrington F; Flynn S; Bradley DM; Porter R; Coggon S; Murkitt G; Searle K; Thomas DR; Watson JM; Martin W; Wu Z; Dawson LA
    Bioorg Med Chem Lett; 2009 Feb; 19(3):837-40. PubMed ID: 19117759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functionalization through lithiation of (S)-N-(1-phenylpropyl)-2-phenylquinoline-4-carboxamide. Application to the labeling with carbon-11 of NK-3 receptor antagonist SB 222200.
    Bennacef I; Perrio C; Lasne MC; Barré L
    J Org Chem; 2007 Mar; 72(6):2161-5. PubMed ID: 17319724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis of new 4-heteroaryl-2-phenylquinolines and their pharmacological activity as NK-2/NK-3 receptor ligands.
    Borioni A; Mustazza C; Sestili I; Sbraccia M; Turchetto L; Del Giudice MR
    Arch Pharm (Weinheim); 2007 Jan; 340(1):17-25. PubMed ID: 17206605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Localization and function of NK(3) subtype tachykinin receptors of layer V pyramidal neurons of the guinea-pig medial prefrontal cortex.
    Simmons MA; Sobotka-Briner CD; Medd AM
    Neuroscience; 2008 Oct; 156(4):987-94. PubMed ID: 18801417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N(alpha)-imidazolylalkyl and pyridylalkyl derivatives of histaprodifen: synthesis and in vitro evaluation of highly potent histamine H(1)-receptor agonists.
    Menghin S; Pertz HH; Kramer K; Seifert R; Schunack W; Elz S
    J Med Chem; 2003 Dec; 46(25):5458-70. PubMed ID: 14640554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.